![Zeynep Eroglu MD](https://res.cloudinary.com/els-assets/image/upload/c_fill_pad,f_auto,g_auto,h_150,q_auto,w_120/v1/practice-update/remote-media/contentimage/22608.jpg)
Zeynep Eroglu MD
Medical Oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida
Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma.
Recent Contributions to PracticeUpdate:
- An Open-Source Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Melanoma
- Neoadjuvant Ipilimumab + Nivolumab for Primary or In Transit Melanoma
- Real-World Survival of Patients With Advanced BRAF V600–Mutated Melanoma Treated With Front-Line BRAF/MEK Inhibitors, Anti–PD-1 Antibodies, or Nivolumab/Ipilimumab
- Improved 5-Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma
- Targeted Therapy Responses in Advanced Melanoma With Rare BRAF Mutations
- No Survival Benefit for Complete Lymph Node Dissection in Sentinel Node-Positive Melanoma
- Dabrafenib, Trametinib, and Pembrolizumab Prolong PFS in BRAF-Mutant Melanoma